Presentation is loading. Please wait.

Presentation is loading. Please wait.

Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul.

Published byEsther Horton Modified over 8 years ago

Similar presentations

Presentation on theme: "Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul."— Presentation transcript:

1 Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul de Souza, M.B., Ph.D., Karim Fizazi, M.D., Ph.D., Paul Mainwaring, M.D., Josep M. Piulats, M.D., Ph.D., Siobhan Ng, M.D., Joan Carles, M.D., Peter F.A. Mulders, M.D., Ph.D., Ethan Basch, M.D., Eric J. Small, M.D., Fred Saad, M.D., Dirk Schrijvers, M.D., Ph.D., Hendrik Van Poppel, M.D., Ph.D., Som D. Mukherjee, M.D., Henrik Suttmann, M.D., Winald R. Gerritsen, M.D., Ph.D., Thomas W. Flaig, M.D., Daniel J. George, M.D., Evan Y. Yu, M.D., Eleni Efstathiou, M.D., Ph.D., Allan Pantuck, M.D., Eric Winquist, M.D., Celestia S. Higano, M.D., Mary-Ellen Taplin, M.D., Youn Park, Ph.D., Thian Kheoh, Ph.D., Thomas Griffin, M.D., Howard I. Scher, M.D., and Dana E. Rathkopf, M.D., for the COU-AA-302 Investigators NEJM Jan 2013 Vol 368 : 138-148 R2 Lee Tae-In/ Prof. Jeong Jae-Heon

2  Metastatic castration-resistant prostate cancer causes approximately 258,400 deaths annualy worldwide  Docetaxel chemotherapy and sipuleucel-T immunotherapy  Abiraterone acetate  Abiraterone acetate is a first-in-class inhibitor of cytochrome P-450c17, a critical enzyme in extragonadal and testicular androgen synthesis

3  Phase 1 and 2 studies in patients who have not received chemotherapy have shown a durable responses, suggesting that the benefits of abiraterone may be optimal in this patient group  In this randomised Phase 3 study, authors evaluate the effects of abiraterone plus prednisone

4  Randomly assigned 1088 patients  Abiraterone + prednisone : 546 patients  Placebo + prednisone : 542 patients  Age of 18 years or older  Metastatic, histologically or cytologically confirmed adenocarcinoma of the prostate  PSA progression  Radiographic progression with / without PSA  Ongoing androgen deprivation  ECOG status 0 or 1

5  Multinational, double-blind, placebo-controlled Abiraterone prednisone Placebo prednisone VS

6  The coprimary efficacy end points were radiographic progression-free survival and overall survival  The prespecified secondary end points were times to opiate use, to initiation of chemotherapy, to a decline in ECOG status, and to PSA progression

7  Efficacy assessments included sequential radiographic imaging to assess radiograhpic progression-free survival and measurement of PSA levels

8

9

10

11

12

13  In patients with metastatic castration- resistant prostate cancer, Abiraterone Abiraterone improved radiographic progression-free survival, overall survival, and significantly delayed clinical decline and initiation of chemotherapy

Download ppt "Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul."

Similar presentations

ASCO G.U. 2014 Lawrence H. Einhorn.

ASCO G.U Lawrence H. Einhorn.
Castrate-resistant prostate cancer (CRPC)

Castrate-resistant prostate cancer (CRPC)
Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.
Methods used to assess and report pain-related endpoints in NDA 21-801 Ethan Basch, MD, MSc Center for Drug Evaluation and Research.

Methods used to assess and report pain-related endpoints in NDA Ethan Basch, MD, MSc Center for Drug Evaluation and Research.
Celestia S. Higano MD, FACP Professor Medicine and Urology University of Washington Member, Fred Hutchison Cancer Research Center The Prostate Net Prostate.

Celestia S. Higano MD, FACP Professor Medicine and Urology University of Washington Member, Fred Hutchison Cancer Research Center The Prostate Net Prostate.
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.

Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
New Hormonal Therapies Roberto Iacovelli The New era of CRPC: few targets for a pletora of agents! ADT Docetaxel Abiraterone Cabazitaxel Alpharadin MDV3100.

New Hormonal Therapies Roberto Iacovelli The New era of CRPC: few targets for a pletora of agents! ADT Docetaxel Abiraterone Cabazitaxel Alpharadin MDV3100.
Www.OncologyEducation.ca Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed.

Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed.
H. I. Scher, T. Beer, C. Higano, M. Taplin, E. Efstathiou, A. Anand, D

H. I. Scher, T. Beer, C. Higano, M. Taplin, E. Efstathiou, A. Anand, D
How should we sequence therapy? Dipartimento Scienze Radiologiche, Oncologiche e Anatomo Patologiche; Oncologia B. “Sapienza” Università di Roma Enrico.

How should we sequence therapy? Dipartimento Scienze Radiologiche, Oncologiche e Anatomo Patologiche; Oncologia B. “Sapienza” Università di Roma Enrico.
Howard M. Sandler, MD University of Michigan Medical School

Howard M. Sandler, MD University of Michigan Medical School
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.

Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.

A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Similar presentations

Ads by Google